Predictiv is a technology company.
Predictiv has raised $1.0M across 1 funding round.
Predictiv has raised $1.0M in total across 1 funding round.
Predictiv is a seed-stage technology company founded in 2020, specializing in personal genomics and predictive medicine through DNA-based digital twin services.[1][3][6] It offers comprehensive whole-genome sequencing of over 20,000 genes to screen for more than 22,000 diseases and simulate responses to 45+ medications, integrating users' health history, lifestyle, and behavior for holistic health predictions and prevention.[1][3][6] Priced at $790 per unit, including genetic counseling, Predictiv serves individuals, healthcare professionals, hospitals, and governments seeking early disease detection, personalized treatment plans, and drug response optimization—covering 99% of known genetic diseases, far exceeding competitors.[3][6]
The company targets the booming healthcare digital twins market, where personalized medicine is projected to reach $10.2 billion by 2032, driven by AI-enabled simulations for chronic conditions like cancer, diabetes, and cardiovascular disease.[1]
Predictiv emerged in 2020 amid the COVID-19 pandemic, developing a highly automated (95%+) genomics pipeline and AI engine validated in the FDA's COVID-19 data challenge, where it ranked 14th overall among major players like Google and UCSF, and 8th in predicting ICU hospitalization length.[3] Founded in Mountain View, California, the company has filed two patents and invested four years in building its platform, starting with fingernail clippings as a simple sample method to unlock health forecasts.[1][3]
While specific founders are not detailed in available sources, Predictiv's early traction stemmed from automating screenings across 20,000 genes against vast disease databases, enabling mass-market access that empowers patients with genetic control and aids clinicians in precise dosing.[3][6]
Predictiv stands out in personal genomics through:
Predictiv rides the explosive growth of healthcare digital twins, a market where software already generated $778.7 million in 2023, fueled by AI, machine learning, and predictive analytics for personalized medicine, drug discovery, and surgical planning.[1] Its timing aligns perfectly with post-pandemic demand for proactive health tech, especially as chronic diseases drive healthcare costs—digital twins enable preemptive interventions, reducing trial-and-error treatments.[1][3]
Market forces like advancing genomics costs, AI integration, and regulatory pushes for precision medicine favor Predictiv, positioning it to influence ecosystems by democratizing whole-genome insights for consumers and providers, potentially accelerating adoption in hospitals and governments.[1][3][6]
Predictiv's momentum in automated, patient-owned digital twins positions it for expansion into broader personalized medicine applications, leveraging its seed-stage funding and patents to scale beyond individuals to enterprise health systems.[1][3] Upcoming trends like AI-driven polygenic risk scoring and real-world evidence integration will amplify its edge, especially as the personalized medicine segment surges toward $10.2 billion by 2032.[1]
Its influence could evolve by setting standards for accessible genomics, shortening sales cycles for health tech adoption, and partnering with pharma for drug simulations—ultimately transforming reactive healthcare into predictive prevention, starting from that overlooked fingernail clipping.[1][3][6]
Predictiv has raised $1.0M in total across 1 funding round.
Predictiv's investors include Draper Associates, Independent, Scott Cunningham.
Predictiv has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $1.0M Seed | Draper Associates, Independent, Scott Cunningham |